The Food and Drug Administration has approved Janssen Pharmaceuticals, Inc.’s Xarelto (rivaroxaban ). Xarelto is intended for the treatment of deep vein thrombosis (DVT). If all or part of a DVT breaks off, it can travel to and lodge in the lungs, and can lead to potentially life-threatening consequences.
Please login or register first to view this content.